Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis

Table 2 Regression modelling: Univariate regression

Characteristic	n	95%CI	P value
Gender	142
Female		-
Male		26, 49	< 0.001
Age (years)	142	-0.72, 0.73	> 0.9
Treatment	142
Lactulose alone		-
Rifaximin-α		-3.4, 20	0.2
Viral hepatitis	141	-5.0, 18	0.3
Alcohol	141	-3.9, 21	0.2
Non-alcoholic fatty liver disease	141	-18, 13	0.8
Other	141	-17, 9.7	0.6
HCV eradication occurred during follow up	142
No		-
Yes		-19, 52	0.4
Hepatocellular carcinoma	141
No		-
Yes		1.8, 25	0.024
MELD score	141	-1.5, 0.69	0.5
Ascites	140
None		-
Diuretic-controlled		-14, 17	0.8
Paracentesis		-20, 8.5	0.4
Charlson co-morbidity score	141	-2.2, 4.9	0.4
Baseline BMI (kg/sq m)	132	0.55, 2.1	0.001
Baseline subjective global assessment	16
A		-
B		-55, 25	0.4
C		-78, 39	0.5
Testosterone therapy during follow up	126
No		-
Yes		-9.5, 40	0.2
Duration of rifaximin-α before follow up SMI (days)	64	-0.05, 0.12	0.4
Days between scans	142	-0.06, 0.03	0.6

HCV: Hepatitis C virus; MELD: Model of end-stage liver disease; BMI: Body mass index; SMI: Skeletal muscle index.